Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation

DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy

(2022) Michael I. Carr et al.   MOLECULAR CANCER RESEARCH

Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy

(2022) Zu Ye et al.   Frontiers in Immunology

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC

(2022) Hirokazu Taniguchi et al.   Cell Reports

Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment

(2022) Luisa Maresca et al.   Cells

cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers

(2022) Christy Hong et al.   NATURE

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy

(2021) Minlin Jiang et al.   Acta Pharmaceutica Sinica B

Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells

(2021) Joanne Wayne et al.   FEBS Journal

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

(2021) Deborah Blythe Doroshow et al.   Nature Reviews Clinical Oncology

DNA Repair Pathways in Cancer Therapy and Resistance

(2021) Lan-ya Li et al.   Frontiers in Pharmacology

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer

(2021) Lukas Gorecki et al.   Cancers

The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials

(2021) Martin Snajdauf et al.   Frontiers in Molecular Biosciences

Inhibition of DNA-PK with AZD7648 sensitizes tumor cells to radiotherapy and induces type I interferon-dependent durable tumor control

(2021) Kyoko Nakamura et al.   CLINICAL CANCER RESEARCH

Interfaces between cellular responses to DNA damage and cancer immunotherapy

(2021) Domenic Pilger et al.   GENES & DEVELOPMENT

Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer

(2021) Sweta Sharma Saha et al.   Cancers

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

(2021) Wei Sun et al.   Frontiers in Oncology

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer

(2021) Zhe Tang et al.   CLINICAL CANCER RESEARCH

WEE1 Inhibitor: Clinical Development

(2021) Anthony Kong et al.   Current Oncology Reports

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

(2021) Eric Haines et al.   Scientific Reports

ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer

(2021) Zongren Wang et al.   Journal for ImmunoTherapy of Cancer

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

(2021) Martina Proctor et al.   Cancers

STING Agonists as Cancer Therapeutics

(2021) Afsaneh Amouzegar et al.   Cancers

The Paradoxical Role of Cellular Senescence in Cancer

(2021) Jing Yang et al.   Frontiers in Cell and Developmental Biology

Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers

(2021) Martina Mang Leng Lei et al.   Frontiers in Cell and Developmental Biology

WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway

(2021) Ensong Guo et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers

(2021) Lingling Zhu et al.   Journal of Hematology & Oncology

Impact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours

(2021) Nura Lutfi et al.   Cancers

APE2 Is a General Regulator of the ATR-Chk1 DNA Damage Response Pathway to Maintain Genome Integrity in Pancreatic Cancer Cells

(2021) Md Akram Hossain et al.   Frontiers in Cell and Developmental Biology

Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations

(2021) Xiangbing Meng et al.   Frontiers in Medicine

Genomic alterations and abnormal expression of APE2 in multiple cancers

(2020) Katherine A. Jensen et al.   Scientific Reports

GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer

(2020) Jintao Lin et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

DNA damage response and resistance of cancer stem cells

(2020) Etna Abad et al.   CANCER LETTERS

Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC).

(2020) Ritu Chaudhary et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting apoptosis in cancer therapy

(2020) Benedito A. Carneiro et al.   Nature Reviews Clinical Oncology

Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation

(2020) Hann-Hsiang Chao et al.   ONCOGENE

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors

(2020) Praveen Vikas et al.   Frontiers in Oncology

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors

(2020) Yu Chen et al.   Molecular Oncology

The Antitumor Effect of Gene-Engineered Exosomes in the Treatment of Brain Metastasis of Breast Cancer

(2020) Minchen Liu et al.   Frontiers in Oncology

Role of DNA repair defects in predicting immunotherapy response

(2020) Jing Zhang et al.   Biomarker Research

Alerting the immune system to DNA damage: micronuclei as mediators

(2020) Kate M. MacDonald et al.   Essays in Biochemistry

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

(2020) Win Topatana et al.   Journal of Hematology & Oncology

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

(2020) Andrea Ghelli Luserna di Rorà et al.   Journal of Hematology & Oncology

PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA

(2020) Emily N. Risdon et al.   ONCOLOGIST

Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer

(2020) Monika Joshi et al.   Cancer Medicine

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment

(2020) Ruibin Yi et al.   Frontiers in Genetics

PARP inhibitors in ovarian cancer: An overview of the practice‐changing trials

(2020) Tiffany Foo et al.   GENES CHROMOSOMES & CANCER

DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity

(2020) Xiaona Sun et al.   Nature Communications

The cGAS-STING Pathway in Hematopoiesis and Its Physiopathological Significance

(2020) Weinian Liao et al.   Frontiers in Immunology

Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity

(2020) Haitang Yang et al.   Cancers

Alterations of DNA damage repair in cancer: from mechanisms to applications

(2020) Minlin Jiang et al.   Annals of Translational Medicine

ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation

(2020) Mengjie Hu et al.   JOURNAL OF CLINICAL INVESTIGATION

Endoplasmic Reticulum Stress Responses in Intratumoral Immune Cells: Implications for Cancer Immunotherapy

(2019) Minkyung Song et al.   TRENDS IN IMMUNOLOGY

Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy

(2019) Qiang Zhang et al.   CANCER RESEARCH

Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors.

(2019) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.

(2019) Manish R. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA-PK as an Emerging Therapeutic Target in Cancer

(2019) Ismail S. Mohiuddin et al.   Frontiers in Oncology

Mechanisms Controlling PD-L1 Expression in Cancer

(2019) Jong-Ho Cha et al.   MOLECULAR CELL

Synthetic lethality as an engine for cancer drug target discovery

(2019) Alan Huang et al.   NATURE REVIEWS DRUG DISCOVERY

The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer

(2019) John Kwon et al.   Cancer Discovery

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

(2019) Katie L. Owen et al.   Cancers

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation

(2018) Kent W. Mouw et al.   BRITISH JOURNAL OF CANCER

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

(2018) Min Yuen Teo et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinically Applicable Inhibitors Impacting Genome Stability

(2018) Anu Prakash et al.   MOLECULES

Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production

(2018) Hiroyasu Konno et al.   ONCOGENE

Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies

(2018) Pierpaola Davalli et al.   Oxidative Medicine and Cellular Longevity

ATR/CHK1 inhibitors and cancer therapy

(2018) Zhaojun Qiu et al.   RADIOTHERAPY AND ONCOLOGY

First PARP Inhibitor Ok'd for Breast Cancer

(2018)   Cancer Discovery

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies

(2018) Jay Friedman et al.   Journal for ImmunoTherapy of Cancer

Mechanisms of PARP inhibitor sensitivity and resistance

(2018) Alan D. D’Andrea   DNA REPAIR

Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour

(2018) Kamal Shaik Fakiruddin et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy

(2018) Lillian Sun et al.   OncoImmunology

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

(2017) Xuenong Ouyang et al.   INVESTIGATIONAL NEW DRUGS

cGAS surveillance of micronuclei links genome instability to innate immunity

(2017) Karen J. Mackenzie et al.   NATURE

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

(2017) Hiro Sato et al.   Nature Communications

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions

(2015) Avi Ashkenazi   JOURNAL OF CLINICAL INVESTIGATION

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis

(2014) Thomas Condamine et al.   JOURNAL OF CLINICAL INVESTIGATION

IFN- -Induced TNF-  Expression Is Regulated by Interferon Regulatory Factors 1 and 8 in Mouse Macrophages

(2014) V. Vila-del Sol et al.   JOURNAL OF IMMUNOLOGY

Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

(2014) E. M. Van Allen et al.   Cancer Discovery

Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

(2013) N J Curtin   BRITISH JOURNAL OF PHARMACOLOGY

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy

(2013) K. Yuan et al.   CLINICAL CANCER RESEARCH

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

(2013) Julio Morales et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

ATM kinase inhibition in glial cells activates the innate immune response and causes neurodegeneration in Drosophila

(2012) A. J. Petersen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells

(2011) M. de Bruyn et al.   CLINICAL CANCER RESEARCH

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

(2010) A Younes et al.   BRITISH JOURNAL OF CANCER

GSK3β: role in therapeutic landscape and development of modulators

(2010) S Phukan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Oxidative stress, inflammation, and cancer: How are they linked?

(2010) Simone Reuter et al.   FREE RADICAL BIOLOGY AND MEDICINE

Inhibition of Ataxia Telangiectasia Mutated Kinase Activity Enhances TRAIL-Mediated Apoptosis in Human Melanoma Cells

(2009) V. N. Ivanov et al.   CANCER RESEARCH

Following TRAIL’s path in the immune system

(2009) Christina Falschlehner et al.   IMMUNOLOGY

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

(2008) Niklas Finnberg et al.   JOURNAL OF CLINICAL INVESTIGATION